stock marker


As concerns about Gilead Sciences (GILD) mount, Maxim’s Jason Kolbert are bullish on the biotech giant’s HIV franchise but not enough to change his Hold rating on the stock:

Associated Press

We recently spoke with GILD management about the launch of Genvoya and other HIV products. Our model now factors in our forecast for patient switch trends from other Gilead products in the HIV marketplace. For example, we have been seeing the cannibalization of Stribild by Genvoya since its launch in both the U.S. and EU in November 2015. Approximately 50% of patients currently on Genvoya were previously on Stribild…


We also expect patients to switch from Atripla to Genvoya, given Atripla is no longer recommended as a first-line HIV treatment by the U.S. Department of Health & Human Services, or DHHS (it was downgraded in April 2015). Atripla had revenues of $3.1B in 2015.

stock marker: Minerva Neurosciences, Inc(NERV)

Advisors’ Opinion:

  • [By Lisa Levin]

    Minerva Neurosciences Inc (NASDAQ: NERV) shares shot up 194 percent to $10.39 after the company revealed positive top line results from a prospective Phase IIb, 12-week, randomized, double-blind, placebo-controlled parallel clinical study evaluating the efficacy, safety and tolerability of MIN-101 in patients with negative symptoms of schizophrenia.

stock marker: Ryder System Inc.(R)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Ryder System (R) tumbled to the bottom of the S&P 500 today after it missed earnings forecasts and cut its full-year guidance.

    Getty Images

    Ryder Systemdropped 14% to $68.28 today, while the S&P 500 0.6% to 2,388.61

    Ryder Systems reported a profit of 82 cents a share, missing forecasts for 84 cents, on sales of $1.75 billion, ahead of forecasts for $1.7 billion. Ryder cut its 2017 guidance to a range of $4.25 to $4.55, below the Street consensus for $5.17.


    Ryder System’s market capitalization fell to $3.7 billion today from $4.2 billion yesterday.

stock marker: L Brands, Inc.(LB)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Many of the losers can be found at the mall, with Gap Stores (GPS) and Abercrombie & Fitch (ANF) continuing to disappoint. The only winner at the mall was Childrens’ Place (PLCE) , but Cramer said he’s not counting out a turnaround at L Brands (LB) .

  • [By WWW.THESTREET.COM]

    The next market worry is retail, with shares of Macy’s (M) falling over 14%, Kohl’s (KSS) down 19% and L Brands (LB) sinking more than 7%. 

    Cramer said the good news is that money is not leaving the stock market, it’s simply moving from the new winners back to the old winners, stocks like Facebook (FB) and Apple (AAPL) , two Action Alerts PLUS holdings.

  • [By Nicholas Rossolillo]

    L Brands (NYSE:LB), owner of brands likeVictoria’s Secret and Bath & Body Works, spun off its last stake in The Limited to private equity company Sun Capital in 2010. Once a thriving fixture of the shopping mall experience, the beleaguered company is throwing in the towel and is now in process of closing down its remaining 250 locations.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was L Brands, Inc. (NYSE: LB) which jumped about 11% to $47.85. The stocks 52-week range is $43.04 to $87.16. Volume was 13.9 million which is above the daily average of around 4.2 million shares.

stock marker: Corcept Therapeutics Incorporated(CORT)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider selling last week:Corcept Therapeutics Inc. (NASDAQ: CORT), Customers Bancorp Inc. (NYSE: CUBI), Ellie Mae Inc. (NYSE: ELLI), Fiserv Inc. (NASDAQ: FISV) and Ulta Beauty Inc. (NASDAQ: ULTA).

Leave a Reply

Your email address will not be published. Required fields are marked *